Abstract: The present invention relates to a compound of formula (I), or a pharmaceutically acceptable salt thereof, wherein Z is OR1 or NR1R2 wherein each of R1 and R2 is independently H, or a hydrocarbyl group; X is an alkylene, alkenylene, or alkynylene group, each of which may be optionally substituted by one or more substituents selected from alkyl, COOH, CO2-alkyl, alkenyl, CN, NH2, hydroxy, halo, alkoxy, CF3 and nitro; Y is a polar functional group selected from OH, NO2, CN, COR3, COOR3, NR3R4, CONR3R4, SO3H, SO2—R3, SO2NR3R4 and CF3, where each of R3 and R4 is independently H or a hydrocarbyl group; A is an aryl or heteroaryl group, each of which may be optionally substituted; and B is (CH2)n where n is 0, 1, 2, 3, 4 or 5; with the proviso that: (i) when A is phenyl, n is 0, and Z is OH, X—Y is other than meta-C?—C—(CH2)2CO2H, meta-C?—C—(CH2)2OH, meta-C?C—(CH2)2CO2Me, meta-(CH2)4CO2H, ortho-CH2CO2H, ortho-(CH2)2CO2H and ortho-(CH2)4CO2H; and (ii) when A is phenyl, n is 0, and Z is OMe, X—Y is other than meta-C?

Abstract: The present invention relates to a compound of formula (I), or a pharmaceutically acceptable salt thereof, wherein Z is OR1 or NR1R2 wherein each of R1 and R2 is independently H, or a hydrocarbyl group; X is an alkylene, alkenylene, or alkynylene group, each of which may be optionally substituted by one or more substituents selected from alkyl, COOH, CO2-alkyl, alkenyl, CN, NH2, hydroxy, halo, alkoxy, CF3 and nitro; Y is a polar functional group selected from OH, NO2, CN, COR3, COOR3, NR3R4, CONR3R4, SO3H, SO2—R3, SO2NR3R4 and CF3, where each of R3 and R4 is independently H or a hydrocarbyl group; A is an aryl or heteroaryl group, each of which may be optionally substituted; and B is (CH2)n where n is 0, 1, 2, 3, 4 or 5; with the proviso that: (i) when A is phenyl, n is 0, and Z is OH, X—Y is other than meta-C?—C—(CH2)2CO2H, meta-C?—C—(CH2)2OH, meta-C?C—(CH2)2CO2Me, meta-(CH2)4CO2H, ortho-CH2CO2H, ortho-(CH2)2CO2H and ortho-(CH2)4CO2H; and (ii) when A is phenyl, n is 0, and Z is OMe, X—Y is other than meta-C?

Abstract: The present invention relates to a novel human protein called phosphatonin, and isolated polynucleotides encoding this protein. Also provided are vectors, host cells, antibodies, and recombinant methods for producing this human protein. The invention further relates to diagnostic and therapeutic methods useful for diagnosing and treating disorders related to this novel human protein.

Abstract: An immune modulator composition and/or pharmaceutical composition comprising a whole cell of a bacterium from the genera Rhodococcus, Gordonia, Nocardia, Dietzia, Tsukamurella and Nocardioides, wherein said immune modulator composition in use modifies a cellular immune response.

Abstract: Apparatus for determining magnetic properties of materials comprises a portable probe (1), an equipment trolley (2) holding cryogenics and electronics and connecting cables (3). The probe (1) comprises a drive coil (4) and a correction coil (5), the drive coil (4) being disposed symmetrically with respect to an inner second-order gradiometer sensor coil (8). Electrical connectors in the form of 2-metre long Belden (1192A) microphone cables (3) are used to connect the apparatus on the equipment trolley (2) to the drive coil (4), the correction coil (5) and the sensor coil (8). The drive coil (4) is driven so as to generate a sinusoidally varying magnetic field. The electronics comprise a flux-locked loop (9), a SQUID controller (10), a data acquisition module (11), which captures and processes the signals and a computer (12). A liquid-nitrogen dewar (13) is supported on the equipment trolley (2) and houses a sensitive SQUID detector (14) and a transfer coil (15) made from copper.

Abstract: The present invention provides a method of identifying a modulator of a voltage gated sodium channel (VGSC), which method comprises bringing into contact a VGSC, a p11 peptide and a test compound under conditions where the VGSC and the p11 peptide are capable of forming a complex in the absence of the test compound; and measuring an activity of the VGSC, wherein a change in the activity of the VGSC relative to the activity in the absence of the test compound indicates that the test compound is a modulator of said VGSC. Compounds identified in such screening methods are proposed for use in the treatment of VGSC-related conditions, for example in the treatment or prevention of pain. Also provided are methods of enhancing the functional expression of a voltage gated sodium channel (VGSC) in a cell comprising the step of increasing the level of p11 in the cell.

Abstract: A method is provided for reducing the extent of or occurrence of long-term adverse health effects in human infants, comprising feeding to said infants when newborn a nutrient-containing-formula providing not more than 1 gram of protein per 100 ml of formula and/or not more than 50 kcal per 100 ml of formula. Also disclosed are methods of administering the infant formulas to reduce the occurrence or extent of insulin resistance in an individual later in life, to reduce the occurrence or extent of obesity or atherosclerosis in an individual later in life, or combinations thereof, by feeding newborn infants the newborn infant formula described herein.

Abstract: A transcutaneous prosthesis includes a first component configured for attachment to a bone, the first component including flutes or grooves on a surface thereof for deterring rotation of the prosthesis within a bone; a second component adapted for location between the bone and the skin, the second component having a surface treatment for stimulation of fibroblastic cell proliferation and attachment of epithelial cells; and a third component adapted for location to extend from the skin surface and is adapted to extend directly from the skin surface in use, the third component having a coating of a non-stick material on an outer surface thereof, the coating having a surface energy that is lower than a surface energy of the first and second components and which is low enough to deter bacterial adhesion.

Abstract: Compounds of formula (I) have been found to be useful as inhibitors of DDAH.

Abstract: The present invention relates to a novel human protein called phosphatonin, and isolated polynucleotides encoding this protein. Also provided are vectors, host cells, antibodies, and recombinant methods for producing this human protein. The invention further relates to diagnostic and therapeutic methods useful for diagnosing and treating disorders related to this novel human protein.

Abstract: The present invention relates to a novel human protein called phosphatonin, and isolated polynucleotides encoding this protein. Also provided are vectors, host cells, antibodies, and recombinant methods for producing this human protein. The invention further relates to diagnostic and therapeutic methods useful for diagnosing and treating disorders related to this novel human protein.

Abstract: An aqueous solution or at least one polyether polyol in a fluid for administration to a mammal, such as a human being, wherein the at least one polyether polyol has a molecular weight of from 200 to 4000 and is dissolved in the aqueous fluid in a concentration of from 0.01 to 10 mg/ml, preferably from 1 to 10 mg/ml.

Abstract: This invention describes a technique and apparatus to use any tuneable laser to generate a specified output frequency without controlling its temperature. This technique only involves a thermal sensor and a controller a determine the current(s) of voltage(s) applied to the grating or tuning section(s) to obtain the required wavelength. The control loop can be implemented using a programmed microprocessor, an amplifier and a low pass filter.

Abstract: The present invention relates to a compound of formula (I), or a pharmaceutically acceptable salt thereof, wherein Z is OR1 or NR1R2 wherein each of R1 and R2 is independently H, or a hydrocarbyl group; X is an alkylene, alkenylene, or alkynylene group, each of which may be optionally substituted by one or more substituents selected from alkyl, COOH, CO2-alkyl, alkenyl, CN, NH2, hydroxy, halo, alkoxy, CF3 and nitro; Y is a polar functional group selected from OH, NO2, CN, COR3, COOR3, NR3R4, CONR3R4, SO3H, SO2—R3, SO2NR3R4 and CF3, where each of R3 and R4 is independently H or a hydrocarbyl group; A is an aryl or heteroaryl group, each of which may be optionally substituted; and B is (CH2)n where n is 0, 1, 2, 3, 4 or 5; with the proviso that: (i) when A is phenyl, n is 0, and Z is OH, X—Y is other than meta-C?—C—(CH2)2CO2H, meta-C?—C—(CH2)2OH, meta-C?C—(CH2)2CO2Me, meta-(CH2)4CO2H, ortho-CH2CO2H, ortho-(CH2)2CO2H and ortho-(CH2)4CO2H; and (ii) when A is phenyl, n is 0, and Z is OMe, X—Y is other than meta-C?

Abstract: The invention relates to the use of a Mechano Growth Factor (MGF) polypeptide or a polynucleotide encoding an MGF polypeptide in the manufacture of a medicament for the prevention or limitation of myocardial damage in response to ischemia or mechanical overload of the heart by preventing or limiting apoptosis in the myocardium.

Abstract: A method of transmission of radio signals over all types of graded-index multimode fibre is provided. The method comprises launching optical radiation into the core of the multimode fibre away from the centre of the core so as to strongly excite a subset of the available modes of the multimode fibre. The subset of modes excited are within a small number of mode groups and thus have similar propagation constants leading to a reduction in modal dispersion and modal interference and smoothing of the frequency response passband region beyond the fibres specified 3 dB base band bandwidth assisting RF transmission and recovery from this region.

Abstract: Disclosed are newborn infant formulas comprising fat, carbohydrate, and from 0.5 to 2.5 g of protein per 100 ml of formula, wherein the formula has a caloric density of from 25 to 50 kcal per 100 ml of formula. Also disclosed are methods of administering the infant formulas to provide newborns with optimal nutrition, to reduce the occurrence or extent of insulin resistance in an individual later in life, to reduce the occurrence or extent of atherosclerosis or coronary artery disease in an individual later in life, or combinations thereof, by feeding newborn infants the newborn infant formula described herein.

Abstract: It has been demonstrated that the level of asymmetric dimethylarginine (ADMA) increases in women that subsequently develop pre-eclampsia or whose fetus subsequently develops intrauterine growth restriction (IUGR) and that ADMA plays a key role in the development of maternal hypertension. Accordingly, the level of ADMA in a pregnant woman can be used to determine whether or not a pregnant woman is at risk of developing pre-eclampsia or whether or not a fetus is at risk of developing IUGR. Furthermore, antagonists of ADMA activity are useful in the inhibition or prevention of pre-eclampsia or inhibition or prevention of IUGR.

Abstract: A transcutaneous prosthesis includes a first component shaped for implantation into a bone, the first component including flutes or grooves on a surface thereof for deterring rotation of the prosthesis within a bone; a second component adapted for location between the bone and the skin, the second component having a surface treatment for stimulation of fibroblastic cell proliferation and attachment of epithelial cells; and a third component adapted for location to extend from the skin surface and is adapted to extend directly from the skin surface in use, the third component having a coating of a non-stick material on an outer surface thereof, the coating having a surface energy that is lower than a surface energy of the first and second components and which is low enough to deter bacterial adhesion.

Abstract: A computer network comprising a plurality of terminals (1–4) connected via a communications network 5 is provided. In each of the terminals (1–4) application software (15) for generating XML source documents is provided. XML source documents created using the application software (15) are then sent to one of the terminals (4) having stored therein a consistency checker (10). The consistency checker (10) processes the source document together with a set of consistency rules (14) to generate an output presentation identifying data within the source documents which does or does not fulfil the requirements of consistency relationships defined by the consistency rules (14).